JP2012502067A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502067A5
JP2012502067A5 JP2011526310A JP2011526310A JP2012502067A5 JP 2012502067 A5 JP2012502067 A5 JP 2012502067A5 JP 2011526310 A JP2011526310 A JP 2011526310A JP 2011526310 A JP2011526310 A JP 2011526310A JP 2012502067 A5 JP2012502067 A5 JP 2012502067A5
Authority
JP
Japan
Prior art keywords
group
hydrogen
halogen
alkyl
perhaloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/056519 external-priority patent/WO2010030785A2/en
Publication of JP2012502067A publication Critical patent/JP2012502067A/ja
Publication of JP2012502067A5 publication Critical patent/JP2012502067A5/ja
Pending legal-status Critical Current

Links

JP2011526310A 2008-09-10 2009-09-10 疾患の治療のためのヒスタミン受容体の複素環阻害剤 Pending JP2012502067A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9582608P 2008-09-10 2008-09-10
US61/095,826 2008-09-10
US23174909P 2009-08-06 2009-08-06
US61/231,749 2009-08-06
PCT/US2009/056519 WO2010030785A2 (en) 2008-09-10 2009-09-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2012502067A JP2012502067A (ja) 2012-01-26
JP2012502067A5 true JP2012502067A5 (enExample) 2012-11-01

Family

ID=42005738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526310A Pending JP2012502067A (ja) 2008-09-10 2009-09-10 疾患の治療のためのヒスタミン受容体の複素環阻害剤

Country Status (14)

Country Link
US (2) US20100120741A1 (enExample)
EP (1) EP2324029A4 (enExample)
JP (1) JP2012502067A (enExample)
KR (1) KR20110095857A (enExample)
CN (1) CN102388044A (enExample)
AR (1) AR073574A1 (enExample)
AU (1) AU2009291719A1 (enExample)
CA (1) CA2735369A1 (enExample)
CL (1) CL2011000431A1 (enExample)
MX (1) MX2011002264A (enExample)
RU (1) RU2011113419A (enExample)
TW (1) TW201024297A (enExample)
UY (1) UY32111A (enExample)
WO (1) WO2010030785A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
TWI547522B (zh) 2009-07-07 2016-09-01 愛爾康研究有限公司 環氧乙烷環氧丁烷嵌段共聚物組成物
MX2012002426A (es) * 2009-08-26 2012-06-27 Cylene Pharmaceuticals Inc Quinolinas condensadas como moduladores de proteina cinasa.
JP2013053070A (ja) * 2009-11-06 2013-03-21 Takeda Chem Ind Ltd ジヒドロピロロキノリン誘導体
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
DE102010025786A1 (de) * 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
BR112013026744B1 (pt) * 2011-04-21 2022-05-17 Origenis Gmbh Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica
US8859550B2 (en) 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2848154C (en) 2011-09-30 2020-04-28 C&C Research Laboratories Novel heterocyclic derivatives and their uses
CA2850932A1 (en) * 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
CA3217159A1 (en) 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
WO2014152029A2 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
KR20160034403A (ko) * 2013-07-25 2016-03-29 유니버시테트 야기엘론스키 5-ht6 길항제로서의 피롤로퀴놀린 유도체, 및 이의 제조 방법 및 용도
EP3307067B1 (en) * 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
KR102070265B1 (ko) * 2017-01-26 2020-01-28 한국화학연구원 신규한 [1,2,4]트리아졸로[4,3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019200500A1 (zh) 2018-04-15 2019-10-24 苏州大学张家港工业技术研究院 1,2,4-三氮唑及其制备方法
WO2019206242A1 (zh) * 2018-04-27 2019-10-31 北京鼎材科技有限公司 有机电致发光材料及器件
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商C&C新藥研究所 雜環衍生物及其用途
CN109705141B (zh) * 2019-02-20 2020-05-29 苏州大学 一种恶唑并喹啉类化合物及其制备方法与应用
CN114746421A (zh) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
AU2022306671A1 (en) 2021-07-07 2024-01-25 Incyte Corporation Tricyclic compounds as inhibitors of kras
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Krasの阻害剤としての三環式化合物
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Krasの阻害剤としてのナフチリジン化合物
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
CN116969943A (zh) * 2022-04-28 2023-10-31 轩竹生物科技股份有限公司 三并环类二酰甘油激酶抑制剂及其用途
JP2025516926A (ja) * 2022-08-03 2025-05-30 アビスコ セラピューティクス カンパニー リミテッド 窒素含有三縮合環prmt5阻害剤、その製造方法および薬学上の用途
KR20250073451A (ko) * 2022-09-26 2025-05-27 상하이 아페이론 테라퓨틱스 컴퍼니 리미티드 신형 prmt5 억제제 및 그 응용
WO2024069235A2 (en) 2022-09-30 2024-04-04 Sixfold Bioscience Ltd. Compositions containing oligonucleotides with theranostic applications
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053600A (en) * 1973-03-08 1977-10-11 Sandoz, Inc. Tricyclic 1,2,4-triazolo-quinazolines
IN160956B (enExample) * 1982-10-18 1987-08-22 Pfizer
US4495187A (en) * 1982-10-18 1985-01-22 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
AU9651198A (en) * 1997-11-11 1999-05-31 Ono Pharmaceutical Co. Ltd. Fused pyrazine compounds
DE50205888D1 (de) * 2001-12-21 2006-04-27 Jsw Res Forschungslabor Gmbh G Pyrazolyl-substituierte triazolochinoxaline
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2921927B1 (fr) * 2007-10-03 2012-10-12 Univ De Montpellier 1 Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers

Similar Documents

Publication Publication Date Title
JP6694886B2 (ja) 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
JP2013510120A5 (enExample)
JP2010523522A5 (enExample)
US20130065895A1 (en) Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction
JP2011511835A5 (enExample)
JP2013529196A5 (enExample)
JP2013505930A5 (enExample)
JP2018501315A5 (enExample)
RU2011113419A (ru) Гетероциклические ингибиторы рецепторов гистамина для лечения заболевания
JP2014037426A5 (enExample)
JP2011500758A5 (enExample)
JP2017533968A5 (enExample)
JP2017531037A (ja) トリアゾロピリジン化合物および嚢胞性線維症の治療のための方法
JP2007529484A5 (enExample)
JP2014511893A5 (enExample)
JP2009507909A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2013523802A5 (enExample)
JP2013542261A5 (enExample)
JP2013510178A5 (enExample)
JP2010533699A5 (enExample)
CN102388055A (zh) 咪唑并[2,1-b][1,3,4]噻二唑衍生物
JP2013542963A5 (enExample)
JP2015510942A5 (enExample)
JP2012530758A5 (enExample)